Based on the data in this article, the answer is no

Based on the data in this article, the answer is no. vaccines. Pfs25-IMX313 elicited similar quality antibodies to dual-antigen vaccines, but higher antibody titers. Keywords: malaria, Epipregnanolone vaccines, dual-antigen, transmission-blocking, viral-vectors, antibodies Introduction Malaria is a parasitic disease with devastating global health consequences. Malaria incidence is estimated at 214 million cases per year, and mortality has been estimated at 438,000 deaths per year (1). There is a critical need for effective malaria vaccines, especially with new global ambitions for malaria elimination and eradication (2), and the decreasing efficacy of existing malaria control interventions due to drug and insecticide resistance (3, 4). The most clinically advanced malaria vaccine candidate, RTS,S, has completed a phase III clinical trial, demonstrating relatively short-lived protection of 46% against clinical malaria and 34% against severe malaria in children and older infants (5). A recent 4-year follow-up study, which included a booster dose, showed a further reduction in efficacy over time (6). Thus, more effective second-generation vaccines are urgently needed especially those which reduce transmission and incidence, rather than simply reducing morbidity and mortality (7). Transmission-blocking vaccines (TBVs) are widely considered an essential tool for malaria elimination, either on their own or as components of a multistage vaccine or other control interventions (8, 9). TBVs elicit antibodies that target sexual-stage antigens of the parasite or mosquito antigens when taken up by the mosquito, thereby blocking parasite development and preventing the vector from transmitting the disease. Pfs25, the leading TBV candidate antigen, is a 25-kDa protein expressed on the surface of zygotes and ookinetes in the mosquito midgut (10). Pfs25 has elicited high antibody titers and transmission-blocking activity (TBA) in preclinical animal studies (11). In humans, exceptionally high antibody titers against Pfs25 have been required to achieve effective transmission-reducing activity (TRA; reduction in oocyst density) (12). This has been a major Epipregnanolone hurdle to further clinical development of TBVs. Various methods have been utilized to express Pfs25 in an immunogenic form, with variable results, including protein-in-adjuvant formulations, protein conjugate vaccines, DNA vaccines, virus-like particles, and recombinant viral vectors (13). In a phase I clinical trial in 2008, a Pfs25 protein formulated in Montanide ISA51 adjuvant vaccine demonstrated significant TRA, but this required very high antibody titers. Unfortunately, the trial was halted due to safety concerns related to the specific antigenCadjuvant combination (14). We have recently shown that fusion of Pfs25 with a novel molecule IMX313, derived from the oligomerization domain from chicken complement inhibitor protein C4b-binding protein (15), expressed from either viral vectors or as proteinCnanoparticles, had significantly higher immunogenicity and increased TRA compared to monomeric Pfs25 (16). Another potential candidate, Pfs230C has recently demonstrated TBA (reduction in prevalence of infected mosquitoes) comparable to Pfs25 (17). Pfs230C is a portion of the antigen Pfs230, which is expressed in the gamete and gametocyte stages of (17, 18). In earlier studies, we have demonstrated that Pfs25 and Pfs230C antigens induce probably the most efficacious antibodies indicated in viral vectors (16, 17). Another encouraging approach to TBV development could be to incorporate multiple antigens into one vaccine. Antibodies against Pfs28 only have shown TBA/TRA (19, 20), and earlier studies have shown potential synergy between Pfs25 and Pfs28 (19). Consequently, to inform antigen selection for medical development advancement, it is important to determine whether antigen combination would be able to increase Epipregnanolone and/or enhance effectiveness as opposed to the SIRT3 use of a single antigen. While several studies with disease and bacterial vaccines have shown interference, to the best of our knowledge, you will find limited published studies investigating the combination of antigens in malaria. Same stage antigen mixtures that have been tested for blood stage, MSP1 and AMA1, have shown evidence of immune interference from the most immunodominant antigen (21). In addition, Forbes et al. (22) have shown that combining viral Epipregnanolone vectors expressing another combination of malaria antigens, CSP and MSP, had no impact on antibody reactions to either antigen but immune interference was observed with cell-mediated immunity..